london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Subfoveal choroidal thickness changes after intravitreal bevacizumab therapy for neovascular age-related macular degeneration

Poster Details

First Author: C.Ünlü TURKEY

Co Author(s):    G. Erdogan   B. Onal Gunay   B.I. Sezgin Akcay   E. Guney Kardes         0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To evaluate the subfoveal choroidal thickness (SFCT) changes after intravitreal bevacizumab (IVB) therapy for neovascular age-related macular degeneration (AMD) by using enhanced depth imaging spectral-domain optical coherence tomography (EDI-OCT)

Setting:

Istanbul Umraniye Education and Research Hospital, Ophthalmology Department

Methods:

We assessed the medical records of the neovascular AMD patients who received intravitreal bevacizumab (1,25 mg/0,05 ml). SFCT was measured before treatment and at final visit by using EDI OCT. Eyes with neovascular AMD which were administered IVB were grouped as IVB group and unaffected fellow eyes were grouped as control group. Main outcome measure was the change in SFCT and secondary outcome measures were the changes in best corrected visual acuity (BCVA) and central macular thickness (CMT).

Results:

In IVB group, the mean number of injections was 4.3±3.2 (range, 1 to 17) during a mean follow up period of 22.1±13.8 months (range, 3 to 45 months). The mean SFCT in IVB group decreased from 215.8±46.9 µm at baseline to 205.5±51.9 µm at final visit (P=0.012), whereas that in control group decreased from 207.2±42.1 µm at baseline to 205.9±39.5 µm at final visit( P=0.938). The mean BCVA of the IVB group was 0.29±0.28 (logMAR units, 0.79±0.55) at baseline and became 0.26±0.28 (logMAR units, 0.87±0.56) at final visit, which was not significant ( P=0.437). The mean best corrected visual acuities of the control group were 0.51±0.34 (logMAR units, 0.51±0.61) at baseline and 0.53±0.34 (logMAR units, 0.48±0.57) at final visits. The change in logMAR visual acuity was not significant (P=0.741). The mean CMT in IVB group decreased from 321.6±69.1 µm at baseline to 302.4±71.1 µm at final visit (P= 0.115). The mean CMT in control group increased from 261.0±20.4 µm µm at baseline to 288.4±38.4 µm µm at final visit (P= 0.503). There was a significat correlation between final BCVA and final SFCT (P =0.016).

Conclusions:

Subfoveal choroidal thickness decreased after IVB injections in eyes with neovascular AMD compared with unaffected fellow eyes. Final visual acuity correlated significantly with subfoveal choroidal thickness.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy